Young & Partners is an international investment banking firm uniquely dedicated to the chemical and life science industries. The Firm is a licensed broker-dealer and a member of the FINRA and SIPC. It is a highly regarded chemical industry and life sciences investment banking firm that is in its 24th year.

The Firm provides extensive services to large and middle market clients in the areas of:

  • Corporate Business and Financial Strategy Consulting
  • Mergers
  • Acquisitions
  • Divestitures
  • Takeover defense
  • Financial restructuring and bankruptcy advisory services
  • Capital raising through private placements
  • General financial advice

The Firm's activities and projects are highly international in nature.

The senior members of the Firm have completed a large number of transactions and financings for companies on a global basis over many years.

Compared to other investment banks, Young & Partners offers clients advantages in the following categories:

  • One of only a few independent investment banks focused solely on the chemical and life science industries
  • Well recognized and highly regarded in the industry
  • Emphasizes long-term relationships with clients
  • Extensive and focused knowledge of chemical and life science industry M&A and financing dynamics
  • Structured to provide consistent senior attention and involvement for all projects
  • Extensive and centralized senior contacts throughout the industry
  • Flexibility to assist clients in all types of transactions, regardless of size or type
  • The only firm that combines first rate investment banking, deep industry knowledge, and corporate strategy consulting expertise in one firm

The Firm has sponsored the leading Senior Chemical Executive Conference every fall for many years on "Strategic, Financial and Shareholder Issues for Chemical Executives".

The Firm has been hosting an annual "Pharmaceutical Executive Summit" for many years that gathers together senior executives and features speakers on important biotech and pharma topics.

In addition, the Firm selectively engages in principal investing.